{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:51:28Z","timestamp":1790351488192,"version":"4.1.0"},"reference-count":194,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01431","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T08:17:14Z","timestamp":1593764234000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["New Insights Into Immunological Therapy for Retinal Disorders"],"prefix":"10.3389","volume":"11","author":[{"given":"Atsunobu","family":"Takeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh-Hei","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","article-title":"Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in behcet's disease: a multicenter study","volume":"121","author":"Takeuchi","year":"2014","journal-title":"Ophthalmology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","article-title":"Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies","volume":"123","author":"Heier","year":"2016","journal-title":"Ophthalmology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"100827","DOI":"10.1016\/j.preteyeres.2019.100827","article-title":"Progress in treating inherited retinal diseases: early subretinal gene therapy clinical trials and candidates for future initiatives","volume":"30","author":"Garafalo","year":"2019","journal-title":"Prog Retin Eye Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00277-014-2212-z","article-title":"Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial","volume":"94","author":"Kreher","year":"2015","journal-title":"Ann Hematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/cas.13012","article-title":"High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma","volume":"107","author":"Akiyama","year":"2016","journal-title":"Cancer Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/bjh.14848","article-title":"Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma","volume":"179","author":"Kaburaki","year":"2017","journal-title":"Br J Haematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/nri1224","article-title":"Ocular immune privilege: therapeutic opportunities from an experiment of nature","volume":"3","author":"Streilein","year":"2003","journal-title":"Nat Rev Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3109\/09273948.2010.525730","article-title":"Ocular immune privilege in the year 2010: ocular immune privilege and uveitis","volume":"18","author":"Taylor","year":"2010","journal-title":"Ocul Immunol Inflamm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3389\/fimmu.2012.00296","article-title":"The privileged immunity of immune privileged organs: the case of the eye","volume":"3","author":"Benhar","year":"2012","journal-title":"Front Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"100778","DOI":"10.1016\/j.preteyeres.2019.100778","article-title":"Innate immune response in retinal homeostasis and inflammatory disorders","volume":"74","author":"Murakami","year":"2019","journal-title":"Prog Retin Eye Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.2337\/db05-1635","article-title":"Diabetic retinopathy: seeing beyond glucose-induced microvascular disease","volume":"55","author":"Antonetti","year":"2006","journal-title":"Diabetes."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.ophtha.2009.04.026","article-title":"Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity","volume":"116","author":"Sato","year":"2009","journal-title":"Ophthalmology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"10075","DOI":"10.1016\/j.preteyeres.2019.04.002","article-title":"Immune privilege in corneal transplantation","volume":"72","author":"Hori","year":"2019","journal-title":"Prog Retin Eye Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/JLB.3MIR0817-337R","article-title":"Negative regulators that mediate ocular immune privilege","volume":"103","author":"Taylor","year":"2018","journal-title":"J Leukoc Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.4049\/jimmunol.1101634","article-title":"A new look at immune privilege of the eye: dual role for the vision-related molecule retinoic acid","volume":"187","author":"Zhou","year":"2011","journal-title":"J Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fimmu.2016.00037","article-title":"Ocular immune privilege and transplantation","volume":"7","author":"Taylor","year":"2016","journal-title":"Front Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1126\/science.270.5239.1189","article-title":"Fas ligand-induced apoptosis as a mechanism of immune privilege","volume":"270","author":"Griffith","year":"1995","journal-title":"Science."},{"key":"B19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1167\/iovs.08-2536","article-title":"Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism","volume":"50","author":"Sugita","year":"2009","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"6323","DOI":"10.4049\/jimmunol.176.10.6323","article-title":"Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses","volume":"176","author":"Toscano","year":"2006","journal-title":"J Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1189\/jlb.1102535","article-title":"Control of myeloid activity during retinal inflammation","volume":"74","author":"Dick","year":"2003","journal-title":"J Leukoc Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.4049\/jimmunol.0901623","article-title":"Acquisition of T regulatory function in cathepsin L-inhibited T cells by eye-derived CTLA-2alpha during inflammatory conditions","volume":"183","author":"Sugita","year":"2009","journal-title":"J Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1084\/jem.20030097","article-title":"Iris pigment epithelium expressing CD86 (B7-2) directly suppresses T cell activation in vitro via binding to cytotoxic T lymphocyte-associated antigen 4","volume":"198","author":"Sugita","year":"2003","journal-title":"J Exp Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4049\/jimmunol.176.1.118","article-title":"B7+ iris pigment epithelium induce CD8+ T regulatory cells; both suppress CTLA-4+ T cells","volume":"176","author":"Sugita","year":"2006","journal-title":"J Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3389\/fimmu.2017.01686","article-title":"Cellular and molecular mechanisms of anterior chamber-associated immune deviation (ACAID): what we have learned from knockout mice","volume":"8","author":"Vendomele","year":"2017","journal-title":"Front Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/08830180212066","article-title":"Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy","volume":"21","author":"Stein-Streilein","year":"2002","journal-title":"Int Rev Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1471-4906(02)00038-8","article-title":"A central role for peripheral dendritic cells in the induction of acquired thymic tolerance","volume":"24","author":"Goldschneider","year":"2003","journal-title":"Trends Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"20143085","DOI":"10.1098\/rspb.2014.3085","article-title":"Evolution of the immune system in humans from infancy to old age","volume":"282","author":"Simon","year":"2015","journal-title":"Proc Biol Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/j.1365-2567.2005.02239.x","article-title":"The analysis of systemic tolerance elicited by antigen inoculation into the vitreous cavity: vitreous cavity-associated immune deviation","volume":"116","author":"Sonoda","year":"2005","journal-title":"Immunology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/IAE.0b013e3181facfa9","article-title":"Hyalocytes: essential cells of the vitreous cavity in vitreoretinal pathophysiology?","volume":"31","author":"Sakamoto","year":"2011","journal-title":"Retina."},{"key":"B31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/bjo.2004.050658","article-title":"The characterisation of hyalocytes: the origin, phenotype, and turnover","volume":"89","author":"Qiao","year":"2005","journal-title":"Br J Ophthalmol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1750-1172-7-57","article-title":"Uveitis- a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients","volume":"7","author":"Barisani-Asenbauer","year":"2012","journal-title":"Orphanet J Rare Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2492\/inflammregen.33.261","article-title":"The regulation of the differentiation of Th1 and Th17 cells in uveitis","volume":"33","author":"Takeda","year":"2013","journal-title":"Inflam Regen."},{"key":"B34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/25785826.2019.1642080","article-title":"The effectiveness of adalimumab treatment for non-infectious uveitis","volume":"42","author":"Hasegawa","year":"2019","journal-title":"Immunol Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2015.07.001","article-title":"The ocular immunology and uveitis foundation preferred practice patterns of uveitis management","volume":"61","author":"Foster","year":"2016","journal-title":"Surv Ophthalmol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10792-013-9788-5","article-title":"Current and future treatments for behcet's uveitis: road to remission","volume":"34","author":"Mesquida","year":"2014","journal-title":"Int Ophthalmol."},{"key":"B37","first-page":"S149","article-title":"Anti-cytokine biologic treatment beyond anti-TNF in behcet's disease","volume":"32","author":"Arida","year":"2014","journal-title":"Clin Exp Rheumatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","article-title":"Multicenter study of infliximab for refractory uveoretinitis in behcet disease","volume":"130","author":"Okada","year":"2012","journal-title":"Arch Ophthalmol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10384-015-0404-2","article-title":"Association between the major histocompatibility complex and clinical response to infliximab therapy in patients with Behcet uveitis","volume":"59","author":"Kuroyanagi","year":"2015","journal-title":"Jpn J Ophthalmol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitiS (FOCUS) Initiative","volume":"125","author":"Dick","year":"2018","journal-title":"Ophthalmology."},{"key":"B41","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine."},{"key":"B42","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/ard.2006.057406","article-title":"Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis","volume":"66","author":"van der Laken","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA."},{"key":"B45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2018.02.003","article-title":"The immunopathogenesis of chronic and relapsing autoimmune uveitis - lessons from experimental rat models","volume":"65","author":"Diedrichs-Mohring","year":"2018","journal-title":"Prog Retin Eye Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.preteyeres.2012.10.002","article-title":"Immunological homeostasis of the eye","volume":"33","author":"Mochizuki","year":"2013","journal-title":"Prog Retin Eye Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/intimm\/dxm135","article-title":"Differential roles for IFN-gamma and IL-17 in experimental autoimmune uveoretinitis","volume":"20","author":"Yoshimura","year":"2008","journal-title":"Int Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1084\/jem.20071258","article-title":"Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category","volume":"205","author":"Luger","year":"2008","journal-title":"J Exp Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nm1585","article-title":"TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1","volume":"13","author":"Amadi-Obi","year":"2007","journal-title":"Nat Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"9989","DOI":"10.1073\/pnas.1820387116","article-title":"Retinal microglia initiate neuroinflammation in ocular autoimmunity","volume":"116","author":"Okunuki","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"key":"B51","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.exer.2016.10.003","article-title":"Invariant natural killer T cells play dual roles in the development of experimental autoimmune uveoretinitis","volume":"153","author":"Satoh","year":"2016","journal-title":"Exp Eye Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1111\/jcmm.14081","article-title":"CD83(+) CCR7(+) NK cells induced by interleukin 18 by dendritic cells promote experimental autoimmune uveitis","volume":"23","author":"Fu","year":"2019","journal-title":"J Cell Mol Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"12895","DOI":"10.1038\/s41598-017-13412-1","article-title":"NK cells are negatively regulated by sCD83 in experimental autoimmune uveitis","volume":"7","author":"Lin","year":"2017","journal-title":"Sci Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1084\/jem.20141678","article-title":"NK-DC crosstalk controls the autopathogenic Th17 response through an innate IFN-gamma-IL-27 axis","volume":"212","author":"Chong","year":"2015","journal-title":"J Exp Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1189\/jlb.0204114","article-title":"Inducible immune regulation following autoimmune disease in the immune-privileged eye","volume":"77","author":"Kitaichi","year":"2005","journal-title":"J Leukoc Biol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.4049\/jimmunol.1402650","article-title":"Retina-specific T regulatory cells bring about resolution and maintain remission of autoimmune uveitis","volume":"194","author":"Silver","year":"2015","journal-title":"J Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"16941","DOI":"10.1038\/s41598-019-53297-w","article-title":"PD-1(+) melanocortin receptor dependent-Treg cells prevent autoimmune disease","volume":"9","author":"Muhammad","year":"2019","journal-title":"Sci Rep."},{"key":"B58","doi-asserted-by":"publisher","first-page":"671417","DOI":"10.1155\/2015\/671417","article-title":"Macrophages and uveitis in experimental animal models","volume":"2015","author":"Merida","year":"2015","journal-title":"Mediators Inflamm."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.ajpath.2017.12.021","article-title":"Cytokine signaling protein 3 deficiency in myeloid cells promotes retinal degeneration and angiogenesis through arginase-1 up-regulation in experimental autoimmune uveoretinitis","volume":"188","author":"Chen","year":"2018","journal-title":"Am J Pathol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/nn1472","article-title":"ATP mediates rapid microglial response to local brain injury in vivo","volume":"8","author":"Davalos","year":"2005","journal-title":"Nat Neurosci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ni.1703","article-title":"The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis","volume":"10","author":"Franchi","year":"2009","journal-title":"Nat Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1126\/science.272.5262.735","article-title":"The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7)","volume":"272","author":"Surprenant","year":"1996","journal-title":"Science."},{"key":"B63","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood.V97.3.587","article-title":"Nucleotide receptors: an emerging family of regulatory molecules in blood cells","volume":"97","author":"Di Virgilio","year":"2001","journal-title":"Blood."},{"key":"B64","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s10384-018-0587-4","article-title":"Crucial role of P2X7 receptor for effector T cell activation in experimental autoimmune uveitis","volume":"62","author":"Takeda","year":"2018","journal-title":"Jpn J Ophthalmol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nature06175","article-title":"Taking dendritic cells into medicine","volume":"449","author":"Steinman","year":"2007","journal-title":"Nature."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/nm1643","article-title":"Lasker basic medical research award. Dendritic cells: versatile controllers of the immune system","volume":"13","author":"Steinman","year":"2007","journal-title":"Nat Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.imlet.2019.03.016","article-title":"The role of ocular dendritic cells in uveitis","volume":"209","author":"Lin","year":"2019","journal-title":"Immunol Lett."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1167\/iovs.06-0697","article-title":"Identification of novel dendritic cell populations in normal mouse retina","volume":"48","author":"Xu","year":"2007","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.4049\/jimmunol.1101621","article-title":"Local activation of dendritic cells alters the pathogenesis of autoimmune disease in the retina","volume":"188","author":"Heuss","year":"2012","journal-title":"J Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.autrev.2013.09.008","article-title":"Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality?","volume":"13","author":"Van Brussel","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B71","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11926-015-0555-7","article-title":"Cellular therapies in systemic sclerosis: recent progress","volume":"18","author":"van","year":"2016","journal-title":"Curr Rheumatol Rep."},{"key":"B72","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.autrev.2014.10.010","article-title":"Role of dendritic cells in the initiation, progress and modulation of systemic autoimmune diseases","volume":"14","author":"Mackern-Oberti","year":"2015","journal-title":"Autoimmun Rev."},{"key":"B73","doi-asserted-by":"publisher","first-page":"399","DOI":"10.4110\/in.2011.11.6.399","article-title":"Maturation-resistant dendritic cells ameliorate experimental autoimmune uveoretinitis","volume":"11","author":"Oh","year":"2011","journal-title":"Immune Netw."},{"key":"B74","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1167\/iovs.11-9323","article-title":"Aminoimidazole carboxamide ribonucleotide ameliorates experimental autoimmune uveitis","volume":"53","author":"Suzuki","year":"2012","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/archophthalmol.2009.34","article-title":"Suppression of experimental autoimmune uveoretinitis by regulatory dendritic cells in mice","volume":"127","author":"Usui","year":"2009","journal-title":"Arch Ophthalmol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e0138241","DOI":"10.1371\/journal.pone.0138241","article-title":"Dietary omega-3 fatty acids suppress experimental autoimmune uveitis in association with inhibition of Th1 and Th17 cell function","volume":"10","author":"Shoda","year":"2015","journal-title":"PLoS ONE."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e0219405","DOI":"10.1371\/journal.pone.0219405","article-title":"Dendritic cells mediate the anti-inflammatory action of omega-3 long-chain polyunsaturated fatty acids in experimental autoimmune uveitis","volume":"14","author":"Uchi","year":"2019","journal-title":"PLoS ONE."},{"key":"B78","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ni.3632","article-title":"Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells","volume":"18","author":"Heink","year":"2017","journal-title":"Nat Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/eji.1830260323","article-title":"Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells","volume":"26","author":"Heufler","year":"1996","journal-title":"Eur J Immunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","article-title":"Global estimates of diabetes prevalence for 2013 and projections for 2035","volume":"103","author":"Guariguata","year":"2014","journal-title":"Diabetes Res Clin Pract."},{"key":"B81","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.2337\/dc15-2171","article-title":"Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010","volume":"39","author":"Leasher","year":"2016","journal-title":"Diabetes Care."},{"key":"B83","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/157339907779802139","article-title":"Leukocytes in diabetic retinopathy","volume":"3","author":"Chibber","year":"2007","journal-title":"Curr Diabetes Rev."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1002\/jcb.25575","article-title":"Angiogenesis and inflammation crosstalk in diabetic retinopathy","volume":"117","author":"Capitao","year":"2016","journal-title":"J Cell Biochem."},{"key":"B85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajpath.2016.08.022","article-title":"Mechanistic insights into pathological changes in the diabetic retina: implications for targeting diabetic retinopathy","volume":"187","author":"Roy","year":"2017","journal-title":"Am J Pathol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1007\/s00125-005-1799-y","article-title":"Inflammation and endothelial dysfunction are associated with retinopathy: the hoorn study","volume":"48","author":"van Hecke","year":"2005","journal-title":"Diabetologia."},{"key":"B87","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1167\/iovs.11-9119","article-title":"Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis","volume":"53","author":"Nakao","year":"2012","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/bjo.77.11.731","article-title":"Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations","volume":"77","author":"Esser","year":"1993","journal-title":"Br J Ophthalmol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nri3088","article-title":"Transcriptional regulation of macrophage polarization: enabling diversity with identity","volume":"11","author":"Lawrence","year":"2011","journal-title":"Nat Rev Immunol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1167\/iovs.14-16012","article-title":"M2 macrophages enhance pathological neovascularization in the mouse model of oxygen-induced retinopathy","volume":"56","author":"Zhou","year":"2015","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B91","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1136\/bjophthalmol-2014-305321","article-title":"Overexpression of CD163 in vitreous and fibrovascular membranes of patients with proliferative diabetic retinopathy: possible involvement of periostin","volume":"99","author":"Kobayashi","year":"2015","journal-title":"Br J Ophthalmol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1096\/fj.13-229740","article-title":"Periostin promotes the generation of fibrous membranes in proliferative vitreoretinopathy","volume":"28","author":"Ishikawa","year":"2014","journal-title":"Faseb J."},{"key":"B93","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.devcel.2009.01.004","article-title":"The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications","volume":"16","author":"Dejana","year":"2009","journal-title":"Dev Cell."},{"key":"B94","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.preteyeres.2013.02.001","article-title":"Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions","volume":"34","author":"Klaassen","year":"2013","journal-title":"Prog Retin Eye Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ophtha.2008.09.037","article-title":"Association of vitreous inflammatory factors with diabetic macular edema","volume":"116","author":"Funatsu","year":"2009","journal-title":"Ophthalmology."},{"key":"B96","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000320006","article-title":"Mechanisms of ocular angiogenesis and its molecular mediators","volume":"46","author":"Siemerink","year":"2010","journal-title":"Dev Ophthalmol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","article-title":"Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment","volume":"134","author":"Bressler","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2337\/diacare.28.2.445","article-title":"Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab","volume":"28","author":"Sfikakis","year":"2005","journal-title":"Diabetes Care."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1167\/iovs.17-22731","article-title":"A CCR2\/5 inhibitor, PF-04634817, is inferior to monthly ranibizumab in the treatment of diabetic macular edema","volume":"59","author":"Gale","year":"2018","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B100","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamaophthalmol.2018.0179","article-title":"Aqueous humor cytokine levels and anatomic response to intravitreal ranibizumab in diabetic macular edema","volume":"136","author":"Hillier","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1136\/bjophthalmol-2016-309953","article-title":"Aqueous cytokine and growth factor levels indicate response to ranibizumab for diabetic macular oedema","volume":"101","author":"Shimura","year":"2017","journal-title":"Br J Ophthalmol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ajo.2019.04.002","article-title":"Aqueous humor cytokines and long-term response to anti-vascular endothelial growth factor therapy in diabetic macular edema","volume":"206","author":"Felfeli","year":"2019","journal-title":"Am J Ophthalmol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1096\/fj.12-215715","article-title":"Retinopathy in a novel model of metabolic syndrome and type 2 diabetes: new insight on the inflammatory paradigm","volume":"28","author":"Noda","year":"2014","journal-title":"Faseb J."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.2353\/ajpath.2010.090883","article-title":"Characterization of a mouse model of hyperglycemia and retinal neovascularization","volume":"177","author":"Rakoczy","year":"2010","journal-title":"Am J Pathol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1001\/jama.2015.10244","article-title":"Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012","volume":"314","author":"Stoll","year":"2015","journal-title":"JAMA."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.ophtha.2016.03.026","article-title":"Changes in course of retinopathy of prematurity from 1986 to 2013: comparison of three studies in the united states","volume":"123","author":"Quinn","year":"2016","journal-title":"Ophthalmology."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Hellstrom","year":"2013","journal-title":"Lancet."},{"key":"B109","first-page":"233","article-title":"Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc."},{"key":"B110","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s00417-018-4034-5","article-title":"Aqueous cytokine levels associated with severity of type 1 retinopathy of prematurity and treatment response to ranibizumab","volume":"256","author":"Lyu","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/labinvest.2011.141","article-title":"Bone marrow-derived monocyte lineage cells recruited by MIP-1beta promote physiological revascularization in mouse model of oxygen-induced retinopathy","volume":"92","author":"Ishikawa","year":"2012","journal-title":"Lab Invest."},{"key":"B114","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1172\/JCI89893","article-title":"Mast cell hyperactivity underpins the development of oxygen-induced retinopathy","volume":"127","author":"Matsuda","year":"2017","journal-title":"J Clin Invest."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/S0140-6736(06)69740-7","article-title":"Retinitis pigmentosa","volume":"368","author":"Hartong","year":"2006","journal-title":"Lancet."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology."},{"key":"B117","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.cell.2015.03.023","article-title":"Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis","volume":"161","author":"Ait-Ali","year":"2015","journal-title":"Cell."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1016\/j.celrep.2018.04.111","article-title":"Aerobic glycolysis is essential for normal rod function and controls secondary cone death in retinitis pigmentosa","volume":"23","author":"Petit","year":"2018","journal-title":"Cell Rep."},{"key":"B119","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.preteyeres.2017.08.004","article-title":"The mechanism of cone cell death in retinitis pigmentosa","volume":"62","author":"Campochiaro","year":"2018","journal-title":"Prog Retin Eye Res."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1074\/jbc.R111.304428","article-title":"Loss of daylight vision in retinal degeneration: are oxidative stress and metabolic dysregulation to blame?","volume":"287","author":"Punzo","year":"2012","journal-title":"J Biol Chem."},{"key":"B121","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ophtha.2012.07.006","article-title":"Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa","volume":"120","author":"Yoshida","year":"2013","journal-title":"Ophthalmology."},{"key":"B122","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.neuron.2015.05.019","article-title":"Dealing with danger in the CNS: the response of the immune system to injury","volume":"87","author":"Gadani","year":"2015","journal-title":"Neuron."},{"key":"B123","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/0002-9394(88)90050-5","article-title":"Detection of lymphocytes in the vitreous gel of patients with retinitis pigmentosa","volume":"105","author":"Newsome","year":"1988","journal-title":"Am J Ophthalmol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.ajo.2015.02.001","article-title":"Relationship between aqueous flare and visual function in retinitis pigmentosa","volume":"159","author":"Murakami","year":"2015","journal-title":"Am J Ophthalmol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/bjophthalmol-2018-312225","article-title":"Correlation between aqueous flare and residual visual field area in retinitis pigmentosa","volume":"103","author":"Nishiguchi","year":"2019","journal-title":"Br J Ophthalmol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"33921","DOI":"10.1038\/srep33921","article-title":"Increased aqueous flare is associated with thickening of inner retinal layers in eyes with retinitis pigmentosa","volume":"6","author":"Nagasaka","year":"2016","journal-title":"Sci Rep."},{"key":"B127","doi-asserted-by":"publisher","first-page":"154943","DOI":"10.1016\/j.cyto.2019.154943","article-title":"Multiple cytokine analyses of aqueous humor from the patients with retinitis pigmentosa","volume":"127","author":"Lu","year":"2020","journal-title":"Cytokine."},{"key":"B128","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1001\/jama.291.6.704","article-title":"Association between C-reactive protein and age-related macular degeneration","volume":"291","author":"Seddon","year":"2004","journal-title":"JAMA."},{"key":"B129","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3109\/02713683.2012.713153","article-title":"Associations between diabetic retinopathy and plasma levels of high-sensitive C-reactive protein or von Willebrand factor in long-term type 1 diabetic patients","volume":"38","author":"Laursen","year":"2013","journal-title":"Curr Eye Res."},{"key":"B130","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1111\/aos.13502","article-title":"C-Reactive protein and progression of vision loss in retinitis pigmentosa","volume":"96","author":"Murakami","year":"2018","journal-title":"Acta Ophthalmol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1194637","article-title":"Fate mapping analysis reveals that adult microglia derive from primitive macrophages","volume":"330","author":"Ginhoux","year":"2010","journal-title":"Science."},{"key":"B132","doi-asserted-by":"publisher","first-page":"eaap8492","DOI":"10.1126\/sciadv.aap8492","article-title":"Repopulating retinal microglia restore endogenous organization and function under CX3CL1-CX3CR1 regulation","volume":"4","author":"Zhang","year":"2018","journal-title":"Sci Adv."},{"key":"B133","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fncel.2013.00045","article-title":"Origin and differentiation of microglia","volume":"7","author":"Ginhoux","year":"2013","journal-title":"Front Cell Neurosci."},{"key":"B134","doi-asserted-by":"publisher","first-page":"E11359","DOI":"10.1073\/pnas.1807123115","article-title":"Permanent neuroglial remodeling of the retina following infiltration of CSF1R inhibition-resistant peripheral monocytes","volume":"115","author":"Paschalis","year":"2018","journal-title":"Proc Natl Acad Sci USA."},{"key":"B135","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2174\/1574888X09666131219115125","article-title":"Survival and migration of pre-induced adult human peripheral blood mononuclear cells in retinal degeneration slow (rds) mice three months after subretinal transplantation","volume":"9","author":"Peng","year":"2014","journal-title":"Curr Stem Cell Res Ther."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.15252\/emmm.201505298","article-title":"Microglial phagocytosis of living photoreceptors contributes to inherited retinal degeneration","volume":"7","author":"Zhao","year":"2015","journal-title":"EMBO Mol Med."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/glia.23016","article-title":"Microglial phagocytosis and activation underlying photoreceptor degeneration is regulated by CX3CL1-CX3CR1 signaling in a mouse model of retinitis pigmentosa","volume":"64","author":"Zabel","year":"2016","journal-title":"Glia."},{"key":"B138","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.spinee.2019.08.006","article-title":"In vitro and in vivo evaluation of discogenic cells, an investigational cell therapy for disc degeneration","volume":"20","author":"Silverman","year":"2020","journal-title":"Spine J."},{"key":"B139","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/jcp.20346","article-title":"Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa","volume":"203","author":"Shen","year":"2005","journal-title":"J Cell Physiol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"11300","DOI":"10.1073\/pnas.0604056103","article-title":"Antioxidants reduce cone cell death in a model of retinitis pigmentosa","volume":"103","author":"Komeima","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"B141","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.ophtha.2012.07.008","article-title":"Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa","volume":"120","author":"Yoshida","year":"2013","journal-title":"Ophthalmology."},{"key":"B142","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1167\/iovs.10-6797","article-title":"Edaravone, an ROS scavenger, ameliorates photoreceptor cell death after experimental retinal detachment","volume":"52","author":"Roh","year":"2011","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B143","doi-asserted-by":"publisher","first-page":"e87781","DOI":"10.1172\/jci.insight.87781","article-title":"MUTYH promotes oxidative microglial activation and inherited retinal degeneration","volume":"1","author":"Nakatake","year":"2016","journal-title":"JCI Insight."},{"key":"B144","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.survophthal.2018.03.002","article-title":"A review of the immunologic findings observed in retinitis pigmentosa","volume":"63","author":"McMurtrey","year":"2018","journal-title":"Surv Ophthalmol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.exer.2006.08.017","article-title":"Classical complement activation and acquired immune response pathways are not essential for retinal degeneration in the rd1 mouse","volume":"84","author":"Rohrer","year":"2007","journal-title":"Exp Eye Res."},{"key":"B146","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1242\/bio.021618","article-title":"A novel immunodeficient NOD.SCID-rd1 mouse model of retinitis pigmentosa to investigate potential therapeutics and pathogenesis of retinal degeneration","volume":"6","author":"Mishra","year":"2017","journal-title":"Biol Open."},{"key":"B147","first-page":"93","article-title":"Current concepts in diagnosing\u2018 and managing primary vitreoretinal (intraocular) lymphoma","volume":"15","author":"Chan","year":"2013","journal-title":"Discov Med."},{"key":"B148","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/09273940902957305","article-title":"Epidemiology and clinical features of intraocular lymphoma","volume":"17","author":"Mochizuki","year":"2009","journal-title":"Ocul Immunol Inflamm."},{"key":"B149","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/107327489800500403","article-title":"Intraocular lymphoma","volume":"5","author":"Bardenstein","year":"1998","journal-title":"Cancer Control."},{"key":"B150","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1111\/j.1755-3768.2009.01797.x","article-title":"Diagnosis of systemic metastatic retinal lymphoma","volume":"89","author":"Cao","year":"2011","journal-title":"Acta Ophthalmol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.survophthal.2013.12.001","article-title":"Primary intraocular lymphoma","volume":"59","author":"Sagoo","year":"2014","journal-title":"Surv Ophthalmol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/OPTH.S159014","article-title":"Primary vitreoretinal lymphoma: prevalence, impact, and management challenges","volume":"13","author":"Venkatesh","year":"2019","journal-title":"Clin Ophthalmol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/bjh.14025","article-title":"How we diagnose and treat vitreoretinal lymphoma","volume":"173","author":"Fend","year":"2016","journal-title":"Br J Haematol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/neuonc\/noy193","article-title":"Introduction of novel agents in the treatment of primary CNS lymphoma","volume":"21","author":"Grommes","year":"2019","journal-title":"Neuro Oncol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/neuonc\/nor186","article-title":"Cognitive functions in primary CNS lymphoma after single or combined modality regimens","volume":"14","author":"Correa","year":"2012","journal-title":"Neuro Oncol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood-2016-01-650101","article-title":"The role of whole brain radiation in primary CNS lymphoma","volume":"128","author":"Kasenda","year":"2016","journal-title":"Blood."},{"key":"B157","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature."},{"key":"B158","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.seminhematol.2015.01.005","article-title":"The genetic landscape of diffuse large B-cell lymphoma","volume":"52","author":"Pasqualucci","year":"2015","journal-title":"Semin Hematol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood."},{"key":"B160","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1182\/blood-2015-01-620518","article-title":"High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates","volume":"126","author":"Bonzheim","year":"2015","journal-title":"Blood."},{"key":"B161","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/ejh.13191","article-title":"CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential","volume":"102","author":"Yonese","year":"2019","journal-title":"Eur J Haematol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1182\/blood.V96.10.3569","article-title":"Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites","volume":"96","author":"Riemersma","year":"2000","journal-title":"Blood."},{"key":"B163","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med."},{"key":"B164","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00262-008-0591-5","article-title":"Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells","volume":"58","author":"Liu","year":"2009","journal-title":"Cancer Immunol Immunother."},{"key":"B165","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ajo.2005.05.032","article-title":"Diagnostic testing of vitrectomy specimens","volume":"140","author":"Davis","year":"2005","journal-title":"Am J Ophthalmol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10384-012-0150-7","article-title":"Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma","volume":"56","author":"Kimura","year":"2012","journal-title":"Jpn J Ophthalmol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00417-019-04266-6","article-title":"Risk factors for failure of vitrectomy cell block technique in cytological diagnosis of vitreoretinal lymphoma","volume":"257","author":"Ito","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/sj.eye.6702965","article-title":"Cytopathological analysis of vitreous in intraocular lymphoma","volume":"22","author":"Intzedy","year":"2008","journal-title":"Eye."},{"key":"B169","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13000-016-0479-1","article-title":"Diagnostic efficacy of cell block method for vitreoretinal lymphoma","volume":"11","author":"Kase","year":"2016","journal-title":"Diagn Pathol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1001\/archopht.1997.01100160327010","article-title":"Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma","volume":"115","author":"Whitcup","year":"1997","journal-title":"Arch Ophthalmol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cncr.21191","article-title":"Analysis of clonal immunoglobulin heavy chain rearrangements in ocular lymphoma","volume":"104","author":"Baehring","year":"2005","journal-title":"Cancer."},{"key":"B172","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0002-9394(14)70828-1","article-title":"Diagnosis of intraocular lymphoma by flow cytometry","volume":"124","author":"Davis","year":"1997","journal-title":"Am J Ophthalmol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10384-009-0662-y","article-title":"Diagnosis of intraocular lymphoma by polymerase chain reaction analysis and cytokine profiling of the vitreous fluid","volume":"53","author":"Sugita","year":"2009","journal-title":"Jpn J Ophthalmol."},{"key":"B174","first-page":"117","article-title":"Evaluation of the reactive T-cell infiltrate in uveitis and intraocular lymphoma with flow cytometry of vitreous fluid (an American Ophthalmological Society thesis)","volume":"110","author":"Davis","year":"2012","journal-title":"Trans Am Ophthalmol Soc."},{"key":"B175","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1182\/blood.2019000022","article-title":"Single-cell MYD88 sequencing of isolated B cells from vitreous biopsies aids vitreoretinal lymphoma diagnosis","volume":"134","author":"Tan","year":"2019","journal-title":"Blood."},{"key":"B176","doi-asserted-by":"publisher","first-page":"7989","DOI":"10.18632\/oncotarget.14008","article-title":"Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies","volume":"8","author":"Cani","year":"2017","journal-title":"Oncotarget."},{"key":"B177","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/0140-6736(91)91837-K","article-title":"Epstein-Barr virus in AIDS-related primary central nervous system lymphoma","volume":"338","author":"MacMahon","year":"1991","journal-title":"Lancet."},{"key":"B178","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fonc.2019.00109","article-title":"Epstein barr virus associated B-cell lymphomas and iatrogenic lymphoproliferative disorders","volume":"9","author":"Crombie","year":"2019","journal-title":"Front Oncol."},{"key":"B179","first-page":"275","article-title":"Molecular pathology of primary intraocular lymphoma","volume":"101","author":"Chan","year":"2003","journal-title":"Trans Am Ophthalmol Soc."},{"key":"B180","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0161-6420(02)01737-2","article-title":"Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma","volume":"110","author":"Chan","year":"2003","journal-title":"Ophthalmology."},{"key":"B181","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.1167\/iovs.11-8719","article-title":"Immune mediators in vitreous fluids from patients with vitreoretinal B-cell lymphoma","volume":"53","author":"Usui","year":"2012","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B182","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ccell.2019.08.001","article-title":"Age-related gliosis promotes central nervous system lymphoma through CCL19-mediated tumor cell retention","volume":"36","author":"O'Connor","year":"2019","journal-title":"Cancer Cell."},{"key":"B183","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4049\/jimmunol.166.1.42","article-title":"NK T cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance","volume":"166","author":"Sonoda","year":"2001","journal-title":"J Immunol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/sj.leu.2403244","article-title":"Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma","volume":"18","author":"Czarneski","year":"2004","journal-title":"Leukemia."},{"key":"B185","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1182\/blood.V89.3.941","article-title":"Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta","volume":"89","author":"Douglas","year":"1997","journal-title":"Blood."},{"key":"B186","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2013.12.005","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Nishikawa","year":"2014","journal-title":"Curr Opin Immunol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3324\/haematol.2015.139493","article-title":"Role of the tumor microenvironment in mature B-cell lymphoid malignancies","volume":"101","author":"Fowler","year":"2016","journal-title":"Haematologica."},{"key":"B189","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer."},{"key":"B190","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2007.13.5533","article-title":"Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: societe francaise de greffe de moelle osseuse-therapie cellulaire","volume":"26","author":"Soussain","year":"2008","journal-title":"J Clin Oncol."},{"key":"B191","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/annonc\/mdz032","article-title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French oculo-cerebral lymphoma (LOC) network and the lymphoma study association (LYSA)dagger","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol."},{"key":"B192","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1212\/WNL.0000000000001158","article-title":"Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma","volume":"84","author":"Houillier","year":"2015","journal-title":"Neurology."},{"key":"B193","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood."},{"key":"B194","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.1167\/iovs.15-17465","article-title":"Distinct profiles of soluble cytokine receptors between B-cell vitreoretinal lymphoma and uveitis","volume":"56","author":"Takeda","year":"2015","journal-title":"Invest Ophthalmol Vis Sci."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01431\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T08:17:20Z","timestamp":1593764240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01431\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,3]]},"references-count":194,"alternative-id":["10.3389\/fimmu.2020.01431"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01431","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,3]]},"article-number":"1431"}}